Nitasha Sarswat
Cardiovascular Disease · Chicago, ILNPI 1033498167
Payments from drug & device makers
Across 314 payments — averaging $6458.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$1.9M
- Pfizer$54K
- Eidos Therapeutics, Inc.$26K
- Astrazeneca UK Limited$23K
- AstraZeneca$8K
- Novo Nordisk$6K
- plus $14K from 21 others
Across 3 payments — averaging $1490.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 140 | $1,897,249 |
| Pfizer(2 entities) | 47 | $54,273 |
| Eidos Therapeutics, Inc. | 6 | $26,288 |
| Astrazeneca UK Limited | 1 | $22,910 |
| AstraZeneca | 13 | $7,697 |
| Novo Nordisk | 4 | $5,503 |
| Akcea Therapeutics, Inc. | 6 | $4,577 |
| Novo Nordisk AS | 1 | $3,875 |
| Abbott | 47 | $2,451 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,363 |
| Cvrx, Inc. | 6 | $307 |
| Nuwellis, Inc. | 2 | $223 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $222 |
| Abiomed | 3 | $217 |
| Bridgebio Pharma, Inc. | 7 | $208 |
| Impulse Dynamics (USA) Inc. | 1 | $176 |
| Sanofi | 1 | $137 |
| Novartis | 4 | $74 |
| Medtronic(2 entities) | 3 | $56 |
| Amgen | 2 | $41 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Boston Scientific | 1 | $27 |
| Portola Pharmaceuticals, LLC | 1 | $27 |
| United Therapeutics Corporation | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Novo Nordisk US Research & Development, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
How this compares
$2,027,999 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Chicago
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
- Boaz AvitallChicago$663K
- Ravi PatelChicago$488K
- Lubna ChoudhuryChicago$476K
- Akhil NarangChicago$427K
- Amit AminChicago$407K
- Michael DavidsonChicago$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.